Liver Stiffness Testing and Biopsy for Chronic Liver Disease
Part of Digestive system clinical trials.
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 80 years old
- Have chronic liver disease (hepatitis B, fatty liver disease, autoimmune hepatitis, or other chronic liver disease) that needs a liver biopsy
- Be able to tolerate an endoscopic procedure (a camera-guided tube passed down your throat)
- Have blood clotting levels within safe range for biopsy (platelet count above 50, normal clotting time)
- Not have advanced cirrhosis with complications like bleeding, fluid buildup, or confusion
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
This study tests a new wearable patch that uses ultrasound to measure liver stiffness without needing a permanent probe. It could be a more comfortable and convenient way to check your liver health, and results will be compared to the standard FibroScan test.
This study uses a special ultrasound during an endoscopic procedure to measure liver stiffness and fat, and compares it to a standard FibroScan. It aims to see if the new method works as well for people with normal liver health.
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study compares two types of liver scanners that measure liver stiffness (a sign of scarring) to see if a new handheld device works as well as the standard one. If the devices are similar, it may allow easier and more affordable liver monitoring for people with chronic liver disease.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.